Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products

On 16 December 2020 the FDA announced the availability of the final guidance for industry.

This document provides guidance to sponsors and applicants on interacting with the FDA on complex innovative trial design (CID) proposals for drugs or biological products. FDA is issuing this guidance to satisfy, in part, a mandate under section 3021 of the 21st Century Cures Act (Cures Act). In accordance with the Cures Act mandate, this guidance discusses the use of novel trial designs in the development and regulatory review of drugs and biological products, how sponsors may obtain feedback on technical issues related to modeling and simulation, and the types of quantitative and qualitative information that should be submitted for review.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /